A, Boxplots showing the duration of draping, patient positioning, trocar placement, and docking/port training. B, Boxplots showing the durations of dissection, anastomosis, undocking/robot ...
Health and Me on MSN
Semaglutide, other GLP-1 drugs linked to lower colorectal cancer risk: study
Semaglutide reduced colorectal cancer risk among people with inflammatory bowel disease (IBD), as well as those with both IBD ...
Espresso on MSN
Could it be colon cancer? 5 early warning signs to know
Here’s what you need to know about colon cancer, and what you can do to prevent it from affecting your life or the lives of ...
Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced results from two Phase 1/2 ...
TheFly reported on June 5 that Lucid Capital analyst Christopher Liu reduced the price target on CRDF to $4 from $10 while ...
The Korean Association for Cancer Chemotherapy Research (KCSG) unveiled the achievements of domestic multi-center clinical ...
CRDF READ THE FULL CRDF RESEARCH REPORT Updated Results from CRDF-004 Cardiff Oncology, Inc. (NASDAQ: CRDF) presented interim ...
A new medication could double survival time in patients with advanced pancreatic cancer, according to Phase III clinical ...
A new drug targets RAS cancer-causing cells in the pancreas, nearly doubling survival rates in clinical trials. Here's how the drug works.
The St. Lucie News-Tribune on MSN
New pancreatic cancer drug withheld as family fights for access
Daraxonrasib was shown to have “landscape-changing” results in extending life expectancy, according to the American Society ...
The discovery of a drug called daraxonrasib, which a Florida doctor was part of, could have implications for extending ...
VS-7375 (investigational KRAS G12D ON/OFF inhibitor) demonstrates clinical activity with a favorable safety profile in TARGET ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results